# DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

> **NCT03321513** · PHASE3 · COMPLETED · sponsor: **Jaeb Center for Health Research** · enrollment: 270 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** intravitreous aflibercept
- **DRUG:** Bevacizumab + Deferred Aflibercept Group

## Key facts

- **NCT ID:** NCT03321513
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-07
- **Primary completion:** 2021-12-22
- **Final completion:** 2021-12-22
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03321513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03321513, "DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03321513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*